Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pyridostigmine metabolism in man.

× No keyword cloud information.

10 in total

Review 1. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors: L A Pagliaro; L Z Benet
Journal: J Pharmacokinet Biopharm Date: 1975-10

2. The relationship between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigmine, edrophonium and 3-hydroxyphenyltrimethylammonium.

Authors: H E Barber; T N Calvey; K T Muir
Journal: Br J Pharmacol Date: 1979-08 Impact factor: 8.739

3. Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors: K Yamamoto; Y Sawada; T Iga
Journal: J Pharmacokinet Biopharm Date: 1996-08

4. In vitro synthesis of metabolites of 14C-pyridostigmine.

Authors: P A Burdfield; T N Calvey
Journal: Experientia Date: 1974-05-15

Review 5. Clinical pharmacokinetics of cholinesterase inhibitors.

Authors: S M Aquilonius; P Hartvig
Journal: Clin Pharmacokinet Date: 1986 May-Jun Impact factor: 6.447

6. Kinetics of intravenous pyridostigmine in man.

Authors: T N Calvey; K Chan; A Dehghan; N E Williams
Journal: Br J Clin Pharmacol Date: 1981-04 Impact factor: 4.335

7. The pharmacokinetics of pyridostigmine and 3-hydroxy-N-methylpyridinium in the rat: dose-dependent effects after portal vein administration.

Authors: H E Barber; G R Bourne; T N Calvey; K T Muir
Journal: Br J Pharmacol Date: 1975-11 Impact factor: 8.739

8. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors: E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal: J Endocrinol Invest Date: 1989-12 Impact factor: 4.256

9. Pyridostigmine pharmacokinetics: evidence for an apparent capacity limited urinary elimination of the metabolites of pyridostigmine.

Authors: H E Barber; G R Bourne
Journal: Br J Pharmacol Date: 1973-06 Impact factor: 8.739

10. Plasma clearance of neostigmine and pyridostigmine in the dog.

Authors: P R Baker; T N Calvey; K Chan; C M Macnee; K Taylor
Journal: Br J Pharmacol Date: 1978-07 Impact factor: 8.739

10 in total